TegMine develops Antibody-Drug Conjugates (ADCs) targeting cancer-specific glycans and glycoproteins to treat solid tumors. By exploiting these unique markers, we deliver potent cell-killing payloads directly to tumors while simultaneously stripping away the immunosuppressive ligands that shield them from the immune system.
"The alteration in the pattern of sugar metabolism and function of cells in relation to the structural remodeling of glycolipids and glycoproteins are undoubtedly a key to open a secret box of malignancy." — Hakomori & Murakami, 1967 (PNAS)
"History will look back on this field and wonder how people could have been so blind... Glycoscience has been a blind spot in medicine and in biology and in biopharma." — C. Bertozzi, 2022
TegMine is a team of dedicated scientists working to translate cancer glycoscience into meaningful new therapies for patients with unmet needs.
Jeff is a biotech veteran with 17+ years of experience at Merck, Stemcentrx, and AbbVie. He has a proven track record of taking therapeutics from the bench to the clinic, including the FDA-approved vaccine Vaxneuvance, and ADCs targeting DLL3, SEZ6, and PTK7.
We’re looking for passionate scientists, innovators, and problem-solvers who want to do more than just work, they want to make an impact. Ready to help us engineer the next generation of cancer therapies?
